# Safety, Tolerability, and Immunogenicity of a 24-Valent Pneumococcal Conjugate Vaccine (VAX-24) in Healthy Infants

> **NCT05844423** · PHASE2 · COMPLETED · sponsor: **Vaxcyte, Inc.** · enrollment: 802 (actual)

## Conditions studied

- Pneumococcal Vaccines

## Interventions

- **BIOLOGICAL:** 0.5 ml dose of 1.1 mcg VAX-24
- **BIOLOGICAL:** 0.5 ml dose of PCV20
- **BIOLOGICAL:** 0.5 ml dose of 2.2 mcg VAX-24
- **BIOLOGICAL:** 0.5 ml dose of 2.2/4.4 mcg VAX-24

## Key facts

- **NCT ID:** NCT05844423
- **Lead sponsor:** Vaxcyte, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2023-03-29
- **Primary completion:** 2025-08-25
- **Final completion:** 2025-08-25
- **Target enrollment:** 802 (ACTUAL)
- **Last updated:** 2025-09-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05844423

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05844423, "Safety, Tolerability, and Immunogenicity of a 24-Valent Pneumococcal Conjugate Vaccine (VAX-24) in Healthy Infants". Retrieved via AI Analytics 2026-07-25 from https://api.ai-analytics.org/clinical/NCT05844423. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*